10-acetyloxy-benzo[b]-naphtho[2,3-e]-[1,4]dioxine-8-carboxylic acid methyl ester | 596106-19-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 10-acetyloxy-benzo[b]-naphtho[2,3-e]-[1,4]dioxine-8-carboxylic acid methyl ester
• 英文别名: Methyl 10-acetyloxybenzo[b]oxanthrene-8-carboxylate
• CAS: 596106-19-3
• 化学式: C₂₀H₁₄O₆
• 分子量: 350.328
• InChiKey: YXOIZJKKMMZNNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  71.1
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Photochromic benzodioxine fused naphthopyran compounds, compositions and articles containing those naphthopyran compounds
  申请人：Vision-Ease Lens, Inc.

  公开号：US20030168645A1

  公开（公告）日：2003-09-11

  Benzodioxino-naphtho[1,2-b]pyran compounds having particularly advantageous photochromic properties, such as, high sensitivity/coloration, two distinct absorption bands in the 430-500 nm range and 520-620 nm range of the visible spectrum may be generally described as a naphthopyran having a central nucleus of the formula: 1 wherein F is a 1,4-benzodioxine ring 2 with its 2,3 positions fused to the i, j, or k faces; and R 1 and R 2 are the atoms or groups providing photochromic properties to the naphthopyran

  具有特别优越光致变色性能的苯并二氧杂萘[1,2-b]吡喃化合物，例如高灵敏度/着色度，在可见光谱430-500 nm范围和520-620 nm范围内具有两个明显的吸收带，通常可描述为具有以下公式的中心核的萘吡喃：1其中F是1,4-苯并二氧杂萘环2，其2,3位置与i、j或k面融合；而R1和R2是提供光致变色性能的原子或基团。
• Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
  申请人：Pfizer Inc.

  公开号：US20020193612A1

  公开（公告）日：2002-12-19

  Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: 1 where j is 0 or 1 provided that when j is 0, n must be 2; k is 0 or 1; m is 0, 1, or 2; n is 1 or 2; W 1 is —O—; or —S(═O) t —, where t is 0, 1, or 2; or —N(R 3 )—; W 2 is —O—CR A R B — or is absent; Y is ═C(R 1 a )— or —[N (O) k ]— where k is 0 or 1; R A and R B are —H; —F; —CF 3 ; —(C 1 -C 4 ) alkyl; —(C 3 -C 7 ) cycloalkyl; phenyl; or benzyl substituted with 0 to 3 substituents R 10 ; or R A and R B are taken together, but only in the case where m is 1, to form a spiro moiety; R C and R D have the same meaning as R A and R B except that one of them must be —H, R 1 and R 2 are —H; —F; —Cl; —CN; —NO 2 ; —(C 1 -C 4 ) alkyl; —(C 2 -C 4 ) alkynyl; fluorinated —(C 1 -C 3 ) alkyl; —OR 16 ; and —C(═O)NR 22 a R 22 b ; R 3 is —H; —(C 1 -C 3 ) alkyl; phenyl; benzyl; or —OR 16 ; R 4 , R 5 and R 6 in addition to other meanings may be taken together to form, e.g., 2 Q 1 is a saturated or unsaturated carbon ring system that is a 3- to 7-membered monocyclic, or that is a 7- to 12-membered, fused polycyclic; provided that Q 1 is not a discontinuous or restricted biaryl moiety as defined under Q 2 ; where optionally one carbon atom may be replaced by a heteroatom selected from N, O, and S; where optionally a second carbon atom thereof, and further optionally a third carbon atom thereof may be replaced by N; Q 2 is a discontinuous or restricted biaryl moiety consisting of a saturated or unsaturated carbon ring system that is a 3- to 7-membered monocyclic, or that is a 7- to 12-membered, fused polycyclic; where optionally one carbon atom may be replaced by a heteroatom selected from N, O, and S; where optionally a second carbon atom thereof, and further optionally a third carbon atom thereof may be replaced by N; Z is selected from: 3

  这是一段关于治疗哮喘、慢性支气管炎和慢性阻塞性肺疾病等疾病中，通过抑制PDE4来调节嗜酸性粒细胞的激活和脱颗粒的化合物的公式描述。其中j为0或1，当j为0时，n必须为2；k为0或1；m为0、1或2；n为1或2；W1为—O—或—S(═O)t—，其中t为0、1或2；或—N(R3)—；W2为—O—CRARB—或不存在；Y为═C(R1a)—或—[N(O)k]—，其中k为0或1；RA和RB为—H；—F；—CF3；—(C1-C4)烷基；—(C3-C7)环烷基；苯基；或取代有0-3个取代基R10的苄基；或在m为1的情况下RA和RB共同形成螺环基；RC和RD与RA和RB的含义相同，但其中一个必须为—H；R1和R2为—H；—F；—Cl；—CN；—NO2；—(C1-C4)烷基；—(C2-C4)炔基；氟代的—(C1-C3)烷基；—OR16；和—C(═O)NR22aR22b；R3为—H；—(C1-C3)烷基；苯基；苄基；或—OR16；除了其他含义外，R4、R5和R6还可以共同形成，例如2；Q1为饱和或不饱和的碳环系统，是一个3-7个成员的单环，或是7-12个成员的融合多环；前提是Q1不是不连续或受限的双芳基基团，如Q2所定义；其中可选地，一个碳原子可以被N、O和S中选择的杂原子所替换；其中可选地，第二个碳原子，进一步可选地，第三个碳原子可以被N所替换；Q2为不连续或受限的双芳基基团，由饱和或不饱和的碳环系统组成，是一个3-7个成员的单环，或是7-12个成员的融合多环；其中可选地，一个碳原子可以被N、O和S中选择的杂原子所替换；其中可选地，第二个碳原子，进一步可选地，第三个碳原子可以被N所替换；Z可选择为：3。
• US6649633B2
  申请人：——

  公开号：US6649633B2

  公开（公告）日：2003-11-18
• US6858732B2
  申请人：——

  公开号：US6858732B2

  公开（公告）日：2005-02-22
• US6953810B2
  申请人：——

  公开号：US6953810B2

  公开（公告）日：2005-10-11